© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 07, 2014
Results from the PEARL-II study show treatment-experienced patients with hepatitis C genotype 1b achieved SVR rates of greater than 96% when treated with a combination of ABT 450 with ritonavir, co-formulated with ombitasvir and dasabuvir, without the need for ribavirin.
Patients with celiac disease treated with larazotide acetate experienced improvements in GI symptoms and non-GI symptoms such as headache and fatigue, as well as significant reductions in the number of symptomatic days.
Patients with IBS-D in two phase II trials of eluxadoline experienced sustained improvements in abdominal pain and bowel symptoms at 26 weeks of treatment, with mild side effects.
May 06, 2014
Fecal microbiota transplants appear safe and patients tolerate them well in trials, but the evidence isn't there yet to establish overall benefit for treating ulcerative colitis.